Free tool
FAERS Monitor: Ogivri
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761074 or its brand name (Ogivri, Trastuzumab-Dkst). Reports on generic versions are filed under their own applications.
Reports
274
Serious
241
88% of reports
Hospitalization
92
Death reported
47
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death32
- off label use30
- diarrhoea21
- chills18
- disease progression18
- dyspnoea18
- back pain17
- fatigue16
- malaise15
- nausea15
- weight decreased14
- arthralgia13
- neutropenia13
- vomiting13
- hospitalisation12
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 10 |
| 2021 | 46 |
| 2022 | 35 |
| 2023 | 64 |
| 2024 | 58 |
| 2025 | 30 |
| 2026 | 29 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,885 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| chillsSignal | 18 | 11.8 | 7.5 | 168 |
| disease progressionSignal | 18 | 11.7 | 7.5 | 166 |
| neutropeniaSignal | 13 | 7.3 | 4.3 | 65 |
| hospitalisationSignal | 12 | 6.0 | 3.4 | 45 |
| back painSignal | 17 | 5.6 | 3.5 | 61 |
| weight decreasedSignal | 14 | 3.8 | 2.3 | 27 |
| deathSignal | 32 | 2.9 | 2.1 | 38 |
| off label useSignal | 30 | 2.6 | 1.9 | 30 |
| malaiseSignal | 15 | 2.6 | 1.6 | 14 |
| diarrhoeaSignal | 21 | 2.5 | 1.7 | 18 |
| dyspnoeaSignal | 18 | 2.4 | 1.6 | 14 |
| arthralgiaSignal | 13 | 2.4 | 1.4 | 9 |
| vomitingSignal | 13 | 2.1 | 1.2 | 7 |
| fatigue | 16 | 1.6 | 1.0 | 3 |
| nausea | 15 | 1.5 | 0.9 | 2 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.